Atjaunināt sīkdatņu piekrišanu

E-grāmata: Antiarrhythmic Drugs: Mechanisms of Antiarrhythmic and Proarrhythmic Actions

Edited by , Associate editor , Edited by , Associate editor , Edited by , Edited by
  • Formāts: PDF+DRM
  • Izdošanas datums: 06-Dec-2012
  • Izdevniecība: Springer-Verlag Berlin and Heidelberg GmbH & Co. K
  • Valoda: eng
  • ISBN-13: 9783642856242
Citas grāmatas par šo tēmu:
  • Formāts - PDF+DRM
  • Cena: 106,47 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
Antiarrhythmic Drugs: Mechanisms of Antiarrhythmic and Proarrhythmic ActionsPalielināt
  • Formāts: PDF+DRM
  • Izdošanas datums: 06-Dec-2012
  • Izdevniecība: Springer-Verlag Berlin and Heidelberg GmbH & Co. K
  • Valoda: eng
  • ISBN-13: 9783642856242
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

The past 10 years have seen a remarkable change in the approach to cardiac arrhythmias, from a position of confidence and a feeling of well-being about pharmacological treatment to a situation in which there is now marked uncertainty and general apprehension about the role of antiarrhythmic drugs. Until relatively recently the prevailing concept in antiarrhythmic therapy was that arrhythmias could be controlled by drugs which slowed conduction or suppressed automaticity, goals well served by the sodium channel-blocking drugs and glycosides. Drug re­ search was based largely on the development of agents mimicking those already available, but with greater efficacy, fewer side effects or a more favourable phar­ macokinetic profile. The CAST trial stands out as a landmark in the evolution of arrhytmia manage­ ment; rarely has a single trial had such a profound impact not only on clinical prac­ tice, but also on the whole approach of those involved in the research, development and regulation of antiarrhythmic drugs. The results of the CAST trial, designed to redress the shortcomings of earlier trials which had failed to demonstrate the anticipated improvement in mortality post-myocardial infarction with the use of class I agents, are well known. The CAST and CAST II showed an increase in mor­ tality associated with the active agent (encainide, flecainide or morizicine) com­ pared to placebo treatment. They firmly established the potential danger in the use of class I drugs.

Papildus informācija

Springer Book Archives
Basic Mechanisms of Antiarrhythmic Drug Action.- Sodium Channel Blockade
as an Antiarrhythmic Mechanism.- Pharmacology of T and L type Ca2+ Channels
in Cardiac Tissue.- Molecular Biology and Ion Channel Biophysics: Their Role
in Rational Pharmacological Antiarrhythmic Therapy.- Selective
Pharmacological Modification of Repolarizing Currents: Antiarrhythmic and
Proarrhythmic Actions of Agents that Influence Repolarization of the Heart.-
A Shift from Class to Class III Drugs in the Medical Treatment of
Arrhythmias: Wishful Thinking?.- Use Dependence and Reverse Use Dependence of
Antiarrhythmic Agents: Pro-and Antiarrhythmic Actions.- Modulation of
Antiarrhythmic Drug Action by Disease and Injury.- Interaction of Transient
Ischemia with Antiarrhythmic Drugs.- Management of Patients with Sustained
Ventricular Tachyarrhythmias: Differnt Clinical Studies, Different Patients.-
Antiarrhythmic Drug Action: Modulation by Disease and Injury.- Reentrant
Excitation: Pharmacological Interactions.- Pharmacological Modulation of
Reentrant Excitation in Experimental Models.- Reentry in Clinical
Arrhythmias: Mechanisms Responsible for Antiarrhythmic Drug Efficacy.-
Variability of the Arrhythmogenic Substrate: Drug Influences.- Experimental
Models for the Assessment of Antiarrhythmic and Proarrhythmic Drug Action:
Traditional and Newer Models.- Influence of the Autonomic Nervous System on
the Action of Antiarrhythmic Drugs.- Role of Drugs in Torsade de Pointes and
Triggered Activity.- The Study of Pharmacokinetics and Pharmacodynamics as a
Tool for Understanding Mechanisms of Antiarrhythmic Drug Action.-
Electrophysiologic Effects, Clinical Efficacy and Antiarrhythmic and
Proarrhythmic Effects of Sodium Channel Blockers in Patients with Ventricular
Tachyarrhythmias.- Antiarrhythmic VersusProarrhythmic Effects of Class III
Agents.- Novel Antiarrhythmic Drugs.- Electrophysiologic Properties and
Antiarrhythmic Effects of Adenosine and Adenosine Triphosphate.-
Magnesium-Electrophysiological Effects, Antiarrhythmic Properties and
Clinical Applications.- Future Perspectives.- The Classification of
Antiarrhythmic Drugs: How do we Educate the Scientist and the Clinician?.
Biežāk uzdotie jautājumi par e-grāmatām Biežāk uzdotie jautājumi par e-grāmatām
Permanent link: https://www.kriso.lv/db/97836428562422e.html
Keywords: